Pharma Stock Reports Robust Q4 Results, Declares Final Dividend And Expands Presence In Global Markets

Sigachi Industries Limited, a Hyderabad-based pharmaceutical firm, revealed the performance of its subsidiaries for the quarter ended March 31, 2025, highlighting several strategic initiatives alongside a final dividend.

As per Sigachi Industries' expectations in the quarterly earnings report, the company is facing rising operational costs. The earnings report showed that consolidated net profit has increased by almost 7% and is now at Rs 22.67 crores from Rs 21.17 crores YoY. Revenue from operations also increased 23% and is now at Rs 128.2 crores (increased from Rs 104.1 crores in Q4 FY24). Total Expenses have also increased and now stand at Rs 107.7 crores, and have also increased from the previous year's quarter, where expenses were Rs 94.1 crores.

In the nutraceutical and pharmaceutical tailwinds, Sigachi Industries has shown remarkable growth during the fiscal year ending March 2025 as the company's foreseen consolidated profit is hitting Rs 92.31 crore, which is a stellar increase when considering their previous financial year profit of Rs 69.77 crore. This tremendous result is due to the company's expanding product portfolio, further strengthened by operational efficiencies.

The company's Board of Directors has proposed a final dividend of 10 per cent, which means the company will pay Re 0.10 for each equity share having a face value of Re 1. This dividend will be finalised in the next Annual General Meeting (AGM) with the shareholders' approval.

In a bid to augment its in-house integrated pharmaceutical business, the board also made a decision to purchase 1,07,17,672 equity shares of its subsidiary Trimax Bio Sciences Pvt Ltd for 37.22 crores. This purchase comes after Sigachi's conversion of an advance/loan into equity and furthers Sigachi's growth plans in its investment in the high-value Active Pharmaceutical Ingredients (API) sector.

Trimax Bio Sciences recently achieved another noteworthy milestone by receiving the Certificate of Suitability Metformin Hydrochloride from the European Directorate for the Quality of Medicines & Health Care (EDQM). This certification allows Trimax to market Metformin Hydrochloride, which is an important API employed in the treatment of type 2 diabetes in the EU and other jurisdictions that recognize the CEP. This further affirms Sigachi's dedication to global quality control and allows the group to increase its international presence.

On Friday, Sigachi Industries' shares at the BSE closed 1.5% higher at Rs 52.66. The stock still remains 17% lower than a year ago, but has surged by 192% in the past two years. In October 2023, the company had split its equity shares in a 10:1 ratio, which reduced the face value from Rs 10 to Re 1 per share.

With a workforce of over 35 years, Sigachi Industries is a global leader in manufacturing high-end excipients, APIs, blended vitamins, minerals, and even operations & maintenance services. The company implements advanced technologies like spray drying and microencapsulation to ensure better health outcomes through science-backed formulations, innovative nutritional and pharmaceutical solutions worldwide.

Sigachi's strong financial performance, global certifications, strategic acquisitions, and more strengthen his financial performance, enabling Sigachi to be a trusted player in the pharmaceutical and nutraceutical ecosystem.